JPMorgan Chase & Co. downgraded its price target for Viking Therapeutics (NASDAQ:VKTX) from $75 to $65, indicating a potential upside of 88.38%.
This downgrade comes after the biotechnology company's stock was sold by two high-ranking executives in late July.
Viking Therapeutics' pipeline includes VK2809 and VK5211, treatments for metabolic disorders such as NASH and muscle wasting conditions.
More on Stocks
Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.
Market sentiment intelligence for apps, funds & agents
Location
729 55 Ave SW
Calgary AB T2V 0G4
Canada
© 2026 Guavy Inc
